Patents by Inventor Ricarda HANNEN

Ricarda HANNEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Amidated peptides and their deamidated counterparts displayed by HLA-A*02 for use in immunotherapy against different types of cancers
    Patent number: 11969464
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: May 23, 2023
    Date of Patent: April 30, 2024
    Inventors: Jens Hukelmann, Heiko Schuster, Ricarda Hannen, Christoph Schraeder, Jens Fritsche, Franziska Hoffgaard, Daniel Johannes Kowalewski, Oliver Schoor
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240131131
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 18, 2023
    Publication date: April 25, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • Peptides displayed by HLA for use in immunotherapy against different types of cancers
    Patent number: 11957716
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: April 16, 2024
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Ricarda Hannen, Jens Hukelmann, Florian Koehler, Daniel Johannes Kowalewski, Heiko Schuster, Oliver Schoor, Michael Roemer, Chih-Chiang Tsou, Jens Fritsche
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240075118
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 18, 2023
    Publication date: March 7, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240075119
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 22, 2023
    Publication date: March 7, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • Amidated peptides and their deamidated counterparts displayed by HLA-A*02 for use in immunotherapy against different types of cancers
    Patent number: 11904003
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 17, 2023
    Date of Patent: February 20, 2024
    Assignee: Immatics Biotechnologies GMBH
    Inventors: Jens Hukelmann, Heiko Schuster, Ricarda Hannen, Christoph Schraeder, Jens Fritsche, Franziska Hoffgaard, Daniel Johannes Kowalewski, Oliver Schoor
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240024440
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 11, 2023
    Publication date: January 25, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240024441
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 25, 2023
    Publication date: January 25, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240016910
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 25, 2023
    Publication date: January 18, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240016913
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 30, 2023
    Publication date: January 18, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240016912
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 30, 2023
    Publication date: January 18, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240016907
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 10, 2023
    Publication date: January 18, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240016906
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 10, 2023
    Publication date: January 18, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240016911
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 25, 2023
    Publication date: January 18, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20240016909
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 18, 2023
    Publication date: January 18, 2024
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20230414734
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 30, 2023
    Publication date: December 28, 2023
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • Amidated peptides and their deamidated counterparts displayed by HLA-A*02 for use in immunotherapy against different types of cancers
    Patent number: 11833195
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 29, 2021
    Date of Patent: December 5, 2023
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Jens Hukelmann, Heiko Schuster, Ricarda Hannen, Christoph Schraeder, Jens Fritsche, Franziska Hoffgaard, Daniel Johannes Kowalewski, Oliver Schoor
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20230338488
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 23, 2023
    Publication date: October 26, 2023
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • AMIDATED PEPTIDES AND THEIR DEAMIDATED COUNTERPARTS DISPLAYED BY HLA-A*02 FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20230285525
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 102, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 17, 2023
    Publication date: September 14, 2023
    Inventors: Jens HUKELMANN, Heiko SCHUSTER, Ricarda HANNEN, Christoph SCHRAEDER, Jens FRITSCHE, Franziska HOFFGAARD, Daniel Johannes KOWALEWSKI, Oliver SCHOOR
  • PEPTIDES DISPLAYED BY HLA FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS
    Publication number: 20220226376
    Abstract: The invention relates to a peptide comprising an amino acid sequence selected from the group consisting of (i) SEQ ID NO: 1 to SEQ ID NO: 216, and (ii) a variant sequence thereof which maintains capacity to bind to MHC molecule(s) and/or induce T cells cross-reacting with said variant peptide, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 14, 2022
    Publication date: July 21, 2022
    Inventors: Ricarda HANNEN, Jens HUKELMANN, Florian KOEHLER, Daniel Johannes KOWALEWSKI, Heiko SCHUSTER, Oliver SCHOOR, Michael ROEMER, Chih-Chiang TSOU, Jens FRITSCHE